Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

NCT07400965 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Demodex Blepharitis

Interventions

DRUG: GLK-321 low dose BID
DRUG: GLK-321 mid dose BID
DRUG: GLK-321 high dose BID
DRUG: GLK-321 high dose QD
DRUG: Placebo BID

Sponsor

Glaukos Corporation